date,title,source
Oct-22-18,"VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018",GlobeNewswire
Oct-25-18,"VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study",GlobeNewswire
Oct-29-18,VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results,GlobeNewswire
Oct-29-18,"Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more",American City Business Journals
Nov-12-18,VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression,GlobeNewswire
